Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?

Ender DoğanSedat T FiratRamazan CosarOktay BozkurtMevlude InancMetin Ozkan

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

Progression-free survival was higher in patients who received bevacizumab first followed by anti-EGFR than reverse sequencing in right colon. Overall survival was similar between two groups.

Keyphrases

epidermal growth factor receptor
metastatic colorectal cancer
free survival
vascular endothelial growth factor
tyrosine kinase
advanced non small cell lung cancer
cancer therapy
endothelial cells
small cell lung cancer
single cell
drug delivery
wild type